Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation

Telix Pharmaceuticals Limited has announced that it has signed an asset purchase agreement with antibody engineering firm ImaginAb, Inc. (ImaginAb) to obtain a pipeline of next-generation therapeutic candidates, an innovative proprietary biologics technology platform, and a protein engineering and discovery research facility to boost its current innovation capabilities.

This deal introduces a pipeline of preliminary drug candidates aimed at high-value targets such as DLL3[1] and integrin αvβ6[2], along with various other innovative targets currently under discovery. These next-generation drug candidates align synergistically with Telix's therapeutic pipeline, facilitating expansion into future treatment areas with unmet clinical demands. The obtained intellectual property employs compact engineered antibody formats that allow for precise cancer targeting, paired with rapid tumor absorption and blood elimination.

The deal also encompasses a cutting-edge research facility located in California, manned by a skilled group of experts in discovery, protein engineering, and radiopharmaceutical development. Collectively, these assets will enhance Telix's internal capabilities in antibody engineering and preclinical development, in addition to offering an innovative biologics platform for developing the next generation of Telix's precision medicine and therapeutic products, extending beyond the existing clinical-stage pipeline.

Richard Valeix, Chief Executive Officer, Therapeutics, Telix, said, "The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets and a talented team of subject matter experts will enhance Telix's research and innovation capability now and into the future. This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology."